Biointegrated sensors for long-term, continuous tracking of body chemistry may make health and disease monitoring as easy as turning on your smartphone. Unveiled by Profusa Inc., of South San Francisco, Calif., tiny bioengineered biosensors will soon enable real-time detection of our body's unique chemistry, providing action­able, medical-grade data for personal and medical use for as long as two years at a time. The company's technology and vision were presented at the CES Digital Health Summit, Jan. 6-9 in Las Vegas.

Patients between the ages of 40 and 70 who undergo aortic valve replacement (AVR) may fare better with tissue-based valves than metal-based valves, according to a review article posted online by The Annals of Thoracic Surgery.

The Centers for Medicare and Medicaid Services (CMS) announced Monday that it will be ending the Meaningful Use program that was meant to encourage the adoption of electronic medical records (EMR).

January 14, 2016 — Cornell biomedical engineers have discovered natural triggers that could reduce the chance of life ...

The American Medical Association (AMA) announced that it is investing $15M to become founding partner of a healthcare innovation company — Health2047 Inc.

Even though brain natriuretic peptide (BNP)/pro-BNP and troponin biomarkers are the gold standard for cardiac disease diagnosis, end users will soon see additional alternative biomarkers entering the market, according to analysis from Frost & Sullivan.

Consumers from California, Colorado and Wisconsin filed a nationwide class action lawsuit against Fitbit Inc. alleging the company’s wrist-based “Charge HR” and “Surge” heart rate monitors do not and cannot consistently record accurate heart rates during the intense physical activity for which Fitbit expressly markets the devices.